We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Bellus Health (BLU) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bellus Health is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Bellus Health is one of 1182 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Bellus Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BLU's full-year earnings has moved 1.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BLU has returned about 5.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 13.1%. This means that Bellus Health is outperforming the sector as a whole this year.
Adherex Technologies Inc. (FENC - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 28.4%.
Over the past three months, Adherex Technologies Inc.'s consensus EPS estimate for the current year has increased 10.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bellus Health belongs to the Medical - Biomedical and Genetics industry, which includes 550 individual stocks and currently sits at #104 in the Zacks Industry Rank. Stocks in this group have lost about 24.6% so far this year, so BLU is performing better this group in terms of year-to-date returns.
On the other hand, Adherex Technologies Inc. belongs to the Medical - Drugs industry. This 231-stock industry is currently ranked #105. The industry has moved -22.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Bellus Health and Adherex Technologies Inc. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Bellus Health (BLU) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bellus Health is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Bellus Health is one of 1182 individual stocks in the Medical sector. Collectively, these companies sit at #10 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Bellus Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for BLU's full-year earnings has moved 1.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that BLU has returned about 5.6% since the start of the calendar year. At the same time, Medical stocks have lost an average of 13.1%. This means that Bellus Health is outperforming the sector as a whole this year.
Adherex Technologies Inc. (FENC - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 28.4%.
Over the past three months, Adherex Technologies Inc.'s consensus EPS estimate for the current year has increased 10.9%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bellus Health belongs to the Medical - Biomedical and Genetics industry, which includes 550 individual stocks and currently sits at #104 in the Zacks Industry Rank. Stocks in this group have lost about 24.6% so far this year, so BLU is performing better this group in terms of year-to-date returns.
On the other hand, Adherex Technologies Inc. belongs to the Medical - Drugs industry. This 231-stock industry is currently ranked #105. The industry has moved -22.9% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Bellus Health and Adherex Technologies Inc. as they could maintain their solid performance.